The Immunological Basis of Inflammatory Bowel Disease

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2017 Jan 11

PMID 28070181

Citations 70

Authors

Francesca A R Silva

Bruno L Rodrigues

Maria de Lourdes S Ayrizono

Raquel F Leal

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel diseases (IBDs) are chronic ailments, Crohn's disease and ulcerative colitis being the most important. These diseases present an inflammatory profile and they differ according to pathophysiology, the affected area in the gastrointestinal tract, and the depth of the inflammation in the intestinal wall. The immune characteristics of IBD arise from abnormal responses of the innate and adaptive immune system. The number of Th17 cells increases in the peripheral blood of IBD patients, while Treg cells decrease, suggesting that the Th17/Treg proportion plays an important role in the development and maintenance of inflammation. The purpose of this review was to determine the current state of knowledge on the immunological basis of IBD. Many studies have shown the need for further explanation of the development and maintenance of the inflammatory process.

Citing Articles

Prevalence of HPV in anal cancer: exploring the role of infection and inflammation.

Ebrahimi F, Rasizadeh R, Jafari S, Baghi H Infect Agent Cancer. 2024; 19(1):63.

PMID: 39696546 PMC: 11654204. DOI: 10.1186/s13027-024-00624-0.

The resolvin D2 and omega-3 polyunsaturated fatty acid as a new possible therapeutic approach for inflammatory bowel diseases.

Chaim F, Pascoal L, de Castro M, Palma B, Rodrigues B, Fagundes J Sci Rep. 2024; 14(1):28698.

PMID: 39562789 PMC: 11576872. DOI: 10.1038/s41598-024-80051-8.

The role of PD-1/PD-L1 pathway in ulcerative colitis and changes following tonsil-derived mesenchymal stem cells treatment.

Song E, Joo Y, Jung S, Byeon J, Choe A, Park Y Korean J Intern Med. 2024; 39(6):917-930.

PMID: 39551070 PMC: 11569929. DOI: 10.3904/kjim.2024.019.

Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma.

Singh K, Singh A, Wolkenhauer O, Gupta S Int J Mol Sci. 2024; 25(19).

PMID: 39408929 PMC: 11476582. DOI: 10.3390/ijms251910600.

Genomic insights into pediatric intestinal inflammatory and eosinophilic disorders using single-cell RNA-sequencing.

Keever-Keigher M, Harvey L, Williams V, Vyhlidal C, Ahmed A, Johnston J Front Immunol. 2024; 15:1420208.

PMID: 39192974 PMC: 11347318. DOI: 10.3389/fimmu.2024.1420208.

References

Schirbel A, Fiocchi C . Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis. 2010; 11(5):266-76. DOI: 10.1111/j.1751-2980.2010.00449.x. View

Izcue A, Coombes J, Powrie F . Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006; 212:256-71. DOI: 10.1111/j.0105-2896.2006.00423.x. View

Papadakis K, Targan S . Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000; 119(4):1148-57. DOI: 10.1053/gast.2000.18160. View

Thelemann C, Eren R, Coutaz M, Brasseit J, Bouzourene H, Rosa M . Interferon-γ induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis. PLoS One. 2014; 9(1):e86844. PMC: 3904943. DOI: 10.1371/journal.pone.0086844. View

Bamias G, Cominelli F . Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol. 2007; 23(4):365-9. DOI: 10.1097/MOG.0b013e3281c55eb2. View

Karin M, Ben-Neriah Y . Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000; 18:621-63. DOI: 10.1146/annurev.immunol.18.1.621. View

Poltorak A, Smirnova I, He X, Liu M, Van Huffel C, McNally O . Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis. 1998; 24(3):340-55. DOI: 10.1006/bcmd.1998.0201. View

Strober W, Fuss I . Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011; 140(6):1756-1767. PMC: 3773507. DOI: 10.1053/j.gastro.2011.02.016. View

Fantini M, Becker C, Tubbe I, Nikolaev A, Lehr H, Galle P . Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut. 2005; 55(5):671-80. PMC: 1856126. DOI: 10.1136/gut.2005.072801. View

10.

Boden E, Snapper S . Regulatory T cells in inflammatory bowel disease. Curr Opin Gastroenterol. 2009; 24(6):733-41. DOI: 10.1097/mog.0b013e328311f26e. View

11.

Qiu J, Heller J, Guo X, Chen Z, Fish K, Fu Y . The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2011; 36(1):92-104. PMC: 3268875. DOI: 10.1016/j.immuni.2011.11.011. View

12.

Huang Y, Chen Z . Inflammatory bowel disease related innate immunity and adaptive immunity. Am J Transl Res. 2016; 8(6):2490-7. PMC: 4931145. View

13.

von Mutius E . Allergies, infections and the hygiene hypothesis--the epidemiological evidence. Immunobiology. 2007; 212(6):433-9. DOI: 10.1016/j.imbio.2007.03.002. View

14.

Bar F, Sina C, Hundorfean G, Pagel R, Lehnert H, Fellermann K . Inflammatory bowel diseases influence major histocompatibility complex class I (MHC I) and II compartments in intestinal epithelial cells. Clin Exp Immunol. 2013; 172(2):280-9. PMC: 3628330. DOI: 10.1111/cei.12047. View

15.

Theiss A, Simmons J, Jobin C, Lund P . Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005; 280(43):36099-109. DOI: 10.1074/jbc.M505291200. View

16.

Dotan I . New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010; 28(3):418-23. DOI: 10.1159/000320396. View

17.

Sands B . From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004; 126(6):1518-32. DOI: 10.1053/j.gastro.2004.02.072. View

18.

Baumgart D, Sandborn W . Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369(9573):1641-57. DOI: 10.1016/S0140-6736(07)60751-X. View

19.

Sung M, Park M . Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. World J Gastroenterol. 2013; 19(7):994-1004. PMC: 3582011. DOI: 10.3748/wjg.v19.i7.994. View

20.

Hart A, Al-Hassi H, Rigby R, Bell S, Emmanuel A, Knight S . Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005; 129(1):50-65. DOI: 10.1053/j.gastro.2005.05.013. View